Dermira Inc  

(Public, NASDAQ:DERM)   Watch this stock  
Find more results for KATHLEEN G. SEBELIUS�
+0.43 (1.66%)
After Hours: 26.37 0.00 (0.00%)
Feb 5, 4:49PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 25.43 - 26.57
52 week 14.20 - 35.75
Open 25.80
Vol / Avg. 206,725.00/140,699.00
Mkt cap 776.32M
P/E     -
Div/yield     -
EPS -2.89
Shares 29.92M
Beta     -
Inst. own 90%
Mar 23, 2016
Q4 2015 Dermira Inc Earnings Release (Estimated) Add to calendar
Feb 11, 2016
Dermira Inc at Leerink Partners Global Healthcare Conference - 11:35AM EST - Add to calendar
Nov 10, 2015
Q3 2015 Dermira Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -219.92% -436.64%
Operating margin -222.93% -434.22%
EBITD margin - -433.58%
Return on average assets -32.31% -31.08%
Return on average equity -37.88% -61.43%
Employees 34 -
CDP Score - -


275 Middlefield Rd Ste 150
MENLO PARK, CA 94025-4008
United States - Map
+1-650-4217200 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Dermira, Inc. is a specialty biopharmaceutical company focused on bringing medical dermatology products to dermatologists and their patients. The Company's portfolio of five product candidates includes three late-stage product candidates. The late-stage product candidates are Cimzia (certolizumab pegol), which the Company is developing in collaboration with UCB Pharma S.A. (UCB), DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor, that is approved and marketed by UCB for the treatment of numerous inflammatory diseases spanning multiple medical specialties. DRM04 is a topical, small-molecule anticholinergic product the Company is developing for the treatment of hyperhidrosis or excessive sweating. DRM01 is a topical, small-molecule sebum inhibitor the Company is developing for the treatment of acne.

Officers and directors

Christopher M. Griffith MBA Founder, Vice President - Corporate Development and Strategy
Age: 38
Bio & Compensation  - Reuters
Andrew L. Guggenhime Chief Financial Officer, Chief Operating Officer
Age: 46
Bio & Compensation  - Reuters
Luis C. Pena Founder, Executive Vice President - Product Development
Age: 52
Bio & Compensation  - Reuters
Thomas G. Wiggans Chairman of the Board, Chief Executive Officer, Founder
Age: 63
Bio & Compensation  - Reuters
Eugene A. Bauer M.D. Founder, Chief Medical Officer, Director
Age: 72
Bio & Compensation  - Reuters
Mark D. McDade Director
Age: 59
Bio & Compensation  - Reuters
Kathleen Sebelius Director
Bio & Compensation  - Reuters
David E. Cohen M.D. Independent Director
Age: 50
Bio & Compensation  - Reuters
Frederick B. Craves Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Matthew K. Fust Independent Director
Age: 50
Bio & Compensation  - Reuters